Expedited Pathways Comparisons - US EU CHN
This presentation from Parexel's virtual roundtable, entitled "Making expedited regulatory pathways work for global drug development programs" outlines regional comparisons of expedited pathways in US, EU and China.
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Related Insights
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Playbook
What emerging trends in the FDA’s most coveted designations might tell us
Feb 8, 2024
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
Focusing on value drivers to reduce risk in early-stage drug development
Jan 6, 2025
Webinar
Accelerated Early Phase Decision-Making – Insider Insights to Speed Development
Jan 7, 2025
Article
How emerging biotechs can enter the Chinese market and prosper
Jan 18, 2022
Blog
Proof of product safety and efficacy: how to move ahead successfully in Phase 2 clinical development
Jan 22, 2025
Blog
Overcoming risks in Phase 3 trials to accelerate time to market
Jan 22, 2025
Playbook
Streamlining development in the EU: Strategies for smoother CTA submissions
Feb 27, 2025
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024